TMCnet News
Vantage mHealthcare Strengthens Balance Sheet and Exchanges Debt at a PremiumVantage mHealthcare Inc., (OTCQB:VNTH) ("Vantage") or (the "Company") today announced Vantage has extinguished debt owed to its parent company, Nanobeak. The Vantage Board, after careful consideration, deems it advisable and in the best interests of the Company to issue 4,616,840 shares of Vantage's common stock at a premium price of $0.10 equal to $461,684.00 to Nanobeak in exchange for full cancellation of the debt. The infusions of cash were necessary over the past several months to help with research and improve upon the technology and design used for the advancement of the Vantage Health Sensor in detecting early stage diseases. About Vantage mHealthcare Inc. Vantage mHealthcare Health Inc. - a mobile health technology company - is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a Bluetooth device that works with any smartphone. With its foundations in advanced nanotechnology, the company's first product, the Vantage Health Sensor, which is in development, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The first mobile App is expected to be for lung cancer screening with additional mobile healthcare Apps in the planning stages. The Company has offices in New York City and Mountain View, CA (News - Alert). For more information, please visit http://www.Vantage mHealthcarehealthinc.com This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. Such forward-looking statements may also include statements, among other things, concerning the efficacy, safety and intended utilization of Vantage mHealthcare's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include, among others, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Vantage mHealthcare may not obtain approval to market its product candidates, or outside financing may not be available to meet capital requirements. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's most recent Annual Report on Form 10-K and other periodic and other filings Vantage mHealthcare files with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Vantage mHealthcare assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
